Answers are grounded in this paper and cite their sources.
Retrospective analysis shows baseline IgG levels predict CMV reactivation risk in multiple myeloma patients receiving elranatamab, suggesting targeted monitoring and prevention.
Background The cumulative incidence and risk of cytomegalovirus (CMV) reactivation in patients with relapsed/refractory multiple myeloma (RRMM) receiving elranatamab remain unclear. Methods We retrospectively analyzed RRMM patients treated with elranatamab to assess cumulative incidence and risk factors for CMV reactivation. Results Among 32 patients, the 6‐month cumulative incidence of CMV reactivation was 37.3%. High CMV immunoglobulin G (IgG) titers were significantly associated with CMV reactivation (57.9% vs. 9.1%, p = 0.012), while prophylactic immunoglobulin reduced CMV reactivation risk within high CMV IgG group. Conclusion Baseline CMV IgG titers may help guide risk‐adapted monitoring and prevention strategies during elranatamab therapy.
No takes yet. Share an insight, caveat, or question.
Chiaki Matsumoto (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: